Mass General Brigham researchers find new ways to combat C. difficile
Mass General Brigham researchers at two hospitals found the metabolic strategies C. difficile uses to rapidly colonize the gut and identified ways to combat the disease
This research represents a significant step for better elucidating the interaction between drugs and the gut microbiome:https://t.co/oE2z0BpxBm— GutMicrobiota Health (@GMFHx) March 14, 2023
Researchers uncover metabolic secrets of anaerobes and identify new strategies to treat c. difficile infections: Study offers possibilities for further understanding of microbial metabolites with findings applicable to clinical medicine
A team of investigators has identified metabolic strategies used by Clostridioides difficile to rapidly colonize the gut. The findings identify methods to better prevent and treat the most common cause of antibiotic-associated diarrhea and healthcare-acquired infections (HAIs). The team's approach has implications for understanding broader aspects of microbial metabolism, including responses to antibiotics, and production of important metabolites.
Discontinuation of Postoperative Prophylactic Antibiotics for Endoscopic Endonasal Skull Base Surgery - PubMed
Background Postoperative prophylactic antibiotic usage for endoscopic skull base surgery varies based on the institution as evidence-based guidelines are lacking. The purpose of this study is to determine whether discontinuing postoperative prophylactic antibiotics in endoscopic endonasal cas …
Investigational Oral Microbiome Therapeutic SER-109 and Quality-of-Life in Recurrent C difficile
This secondary analysis of a randomized clinical trial examines the association of SER-109 with health-related quality of life in 182 patients with recurrent Clostridioides difficile infection in the US and Canada.
What is the tolerability profile and rate of recurrent CDI after administrating microbiome therapeutic SER-109 post-antibiotic treatment?
Researchers investigated the tolerability and safety of a microbiome therapy called SER-109 to treat recurrent infections of Clostridioides difficile in adults.
Microbiome therapeutic offers ‘durable’ improvement in quality of life for recurrent CDI
Use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to data in JAMA Network Open.“C. diff infection is associated with poor quality of life (QOL), but improvement in QOL has never been demonstrated in randomized controlled
UK biotech hands off mid-stage C. difficile drug in up to $570M deal
A biotech in the UK has out-licensed a C. difficile candidate to a US biotech for further clinical and commercialization efforts. UK-based Destiny Pharma announced Friday that it is handing NTCD-M3 to Sebela Pharmaceuticals. The deal includes an initial $1 million upfront, $19 million in development milestones, and an additional
Microbial medics diagnose and treat gut inflammation
Engineered microbes show potential for diagnosing and treating diseases. In this issue of Cell Host & Microbe, Zou et al. develop an “intelligent” bac…
Looking Beyond C difficile: The Potential of the Gut Microbiome - Contagionlive.com
Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.
What is the tolerability profile and rate of recurrent CDI after administrating microbiome therapeutic SER-109 post-antibiotic treatment? - News-Medical.Net
Medical News and articles you can trust from around the world. All content is written and reviewed by qualified health, medical and scientific experts.
Targeting the Impossible: A Review of New Strategies against Endospores
Endospore-forming bacteria are ubiquitous, and their endospores can be present in food, in domestic animals, and on contaminated surfaces. Many spore-forming bacteria have been used in biotechnological applications, while others are human pathogens responsible for a wide range of critical clinical i …
Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The deteriorating demographic structure and the increase in the number of antibiotics used in …
Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria
The rising burden of antimicrobial resistance and increasing infectious disease outbreaks, including the recent COVID-19 pandemic, has led to a growing demand for the development of natural products as a valuable source of leading medicinal compounds. There is a wide variety of active constituents f …
The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects
Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r-CDI). This review aims to highlight the future drugs for CDI and their related patented applications. The non-pate …
Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The deteriorating demographic structure and the increase in the number of antibiotics used in …
Bacteriophage discovery to advance biotechnology and biotherapeutics
Nature Reviews Microbiology - This Genome Watch explores how large-scale microbiome studies are facilitating discoveries in bacteriophage biology and functional capabilities that are prime for...
C. difficile Clinical Study 19-0021: C. diff Clinical Trials
Learn about our ongoing C. diff treatment trial: a randomized, double-blind evaluation of CRS3123 vs. Oral Vancomycin for adults with C. difficile Infection.
Safety and Tolerability of SER-109 for Recurrent Clostridioides difficile Infection in Adults
This phase 3, open-label, single-arm trial assesses the safety of SER-109 and the rate of recurrent Clostridioides difficile infection after administration of SER-109 following symptom resolution after antibiotic treatment among adults.
Race To The Cure: Here's Why Acurx Pharmaceuticals Could Win The Battle To Treat C. difficile ($ACXP) | MarketScreener
There's good news, and then there's excellent news. The good news is that Acurx Pharmaceuticals is nearing its Phase 3 trial to get a best-in-class front-line treatment for C. difficile to the... | February 21, 2023
C Difficile Infection Drug Sales Market report during 2023-2032 | By Top Leading Vendors Teva Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Perrigo Pharmaceutical
What is the tolerability profile and rate of recurrent CDI after administrating microbiome therapeutic SER-109 post-antibiotic treatment?
Researchers investigated the tolerability and safety of a microbiome therapy called SER-109 to treat recurrent infections of Clostridioides difficile in adults.
Structure-guided design of a potent Clostridiodes difficile toxin A inhibitor - PubMed
Crystal structures of camelid heavy-chain antibody variable domains (VHHs) bound to fragments of the combined repetitive oligopeptides domain of Clostridiodes difficile toxin A (TcdA) reveal that the C-terminus of VHH A20 was located 30 Å away from the N-terminus of V …
Phase 3 trial provides more positive data for recurrent C diff microbiome drug
SER-109, an investigational microbiome therapeutic for treating recurrent Clostridioides difficile infection, was well tolerated and showed clinical benefit.